📊 BDSX Key Takeaways
Is Biodesix Inc. (BDSX) a Good Investment?
Biodesix exhibits severe financial distress with negative stockholders' equity of -2.5M, persistent operating losses, and significant cash burn despite 24% revenue growth. The company is consuming cash at an unsustainable rate (-23.5M FCF annually) while carrying 50M in long-term debt, creating an acute solvency risk in the near term.
Biodesix is delivering solid top-line growth, but the business remains deeply unprofitable with a -31.5% operating margin, -39.8% net margin, and materially negative free cash flow. The balance sheet is stressed by negative stockholders' equity, meaningful long-term debt, and weak interest coverage, which makes the current growth profile look low quality until the company proves durable operating leverage and cash burn reduction.
Why Buy Biodesix Inc. Stock? BDSX Key Strengths
- Revenue growth of 24.1% YoY demonstrates market demand for diagnostic services
- Current ratio of 1.86x provides near-term liquidity cushion with 19.0M in cash
- Active insider participation (28 Form 4 filings in 90 days) suggests management confidence
- Revenue growth of 24.1% YoY shows continued commercial demand expansion
- Current and quick ratios of 1.86x indicate acceptable near-term liquidity
- EPS improved 29.7% YoY, suggesting losses are narrowing on a per-share basis
BDSX Stock Risks: Biodesix Inc. Investment Risks
- Negative stockholders' equity (-2.5M) indicates technical insolvency and heightened bankruptcy risk
- Operating losses of -27.9M on 88.5M revenue with -39.8% net margin shows business model is fundamentally unprofitable at scale
- Negative free cash flow of -23.5M annually with only 19.0M cash on hand implies liquidity crisis within 12 months without capital raise or operational turnaround
- 50M long-term debt burden is unsustainable given negative cash generation and equity cushion
- Negative stockholders' equity indicates a weakened capital structure and limits financial flexibility
- Operating cash flow of -$23.27M and free cash flow of -$23.53M show the business is still consuming cash heavily
- Long-term debt of $50.01M combined with negative interest coverage increases refinancing and solvency risk
Key Metrics to Watch
- Quarterly cash burn rate and months of cash runway remaining
- Path to operating profitability and gross margin expansion
- Debt refinancing activities and covenant compliance status
- Operating cash flow and free cash flow burn
- Operating margin improvement toward breakeven
Biodesix Inc. (BDSX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Biodesix Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
BDSX Profit Margin, ROE & Profitability Analysis
BDSX vs Healthcare Sector: How Biodesix Inc. Compares
How Biodesix Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Biodesix Inc. Stock Overvalued? BDSX Valuation Analysis 2026
Based on fundamental analysis, Biodesix Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Biodesix Inc. Balance Sheet: BDSX Debt, Cash & Liquidity
BDSX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Biodesix Inc.'s revenue has grown significantly by 62% over the 5-year period, indicating strong business expansion. The most recent EPS of $-6.64 indicates the company is currently unprofitable.
BDSX Revenue Growth, EPS Growth & YoY Performance
BDSX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $18.2M | -$8.7M | $-1.16 |
| Q2 2025 | $17.9M | -$10.8M | $-0.08 |
| Q1 2025 | $14.8M | -$11.1M | $-0.08 |
| Q3 2024 | $13.5M | -$10.3M | $-0.07 |
| Q2 2024 | $11.9M | -$10.8M | $-0.08 |
| Q1 2024 | $9.1M | -$13.6M | $-0.14 |
| Q3 2023 | $11.1M | -$10.9M | $-0.14 |
| Q2 2023 | $11.0M | -$13.4M | $-0.17 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Biodesix Inc. Dividends, Buybacks & Capital Allocation
BDSX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Biodesix Inc. (CIK: 0001439725)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BDSX
What is the AI rating for BDSX?
Biodesix Inc. (BDSX) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BDSX's key strengths?
Claude: Revenue growth of 24.1% YoY demonstrates market demand for diagnostic services. Current ratio of 1.86x provides near-term liquidity cushion with 19.0M in cash. ChatGPT: Revenue growth of 24.1% YoY shows continued commercial demand expansion. Current and quick ratios of 1.86x indicate acceptable near-term liquidity.
What are the risks of investing in BDSX?
Claude: Negative stockholders' equity (-2.5M) indicates technical insolvency and heightened bankruptcy risk. Operating losses of -27.9M on 88.5M revenue with -39.8% net margin shows business model is fundamentally unprofitable at scale. ChatGPT: Negative stockholders' equity indicates a weakened capital structure and limits financial flexibility. Operating cash flow of -$23.27M and free cash flow of -$23.53M show the business is still consuming cash heavily.
What is BDSX's revenue and growth?
Biodesix Inc. reported revenue of $88.5M.
Does BDSX pay dividends?
Biodesix Inc. does not currently pay dividends.
Where can I find BDSX SEC filings?
Official SEC filings for Biodesix Inc. (CIK: 0001439725) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BDSX's EPS?
Biodesix Inc. has a diluted EPS of $-4.67.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BDSX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Biodesix Inc. has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BDSX stock overvalued or undervalued?
Valuation metrics for BDSX: ROE of N/A (sector avg: 15%), net margin of -39.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BDSX stock in 2026?
Our dual AI analysis gives Biodesix Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BDSX's free cash flow?
Biodesix Inc.'s operating cash flow is $-23.3M, with capital expenditures of $259.0K. FCF margin is -26.6%.
How does BDSX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -39.8% (avg: 12%), ROE N/A (avg: 15%), current ratio 1.86 (avg: 2).